Opportunities In Tech And Life Sciences (TU, RCI,VITA, OSIP)

According to Canaccord, Telus Corporation’s (NYSE: TU)(FREE stock trend analysis) Wind Mobile shows a great potential with a unique pricing model which can help expand the subscriber base rapidly. The Buy rating is maintained on Telus but Rogers Communications (NYSE: RCI)(FREE stock trend analysis) is exposed to Wind’s pricing strategy, leading to a Sell rating.

Orthovita’s (NASDAQ: VITA)(FREE stock trend analysis) launch of CORTOSS was weaker than expected. The Buy rating is reiterated but at a lower target of $4.50. Meanwhile, the outlook on OSI Pharmaceuticals (NASDAQ: OSIP)(FREE stock trend analysis) remains positive despite ODAC slamming Tarceva in a front-line maintenance treatment setting. A significant upside potential remains if Tarceva gains traction in a front-line treatment setting, and there is evidence to support this possibility.